Filtered By:
Drug: Clopidogrel
Education: Study

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 1183 results found since Jan 2013.

A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke
J Physiol Pharmacol. 2022 Feb;73(1). doi: 10.26402/jpp.2022.1.11. Epub 2022 Jul 4.ABSTRACTTo investigate the relationship between plasma microRNA-223 expression and platelet reactivity in patients with acute ischemic stroke (AIS) and to evaluate its predictive value in clopidogrel resistance or high on-treatment platelet reactivity (HTPR). A total of 120 patients with acute ischemic stroke were screened in this study, and 60 patients were included in the acute ischemic stroke group according to the inclusion criteria and platelet reactivity after clopidogrel treatment. control group was 60 non-ischemic stroke patients hosp...
Source: Journal of Physiology and Pharmacology - July 6, 2022 Category: Drugs & Pharmacology Authors: D-L Wang X Li R-N Wang Y Sun X-S Xia W-J Tian L Wang Source Type: research

Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Abstract: Tirofiban has been used historically as a bridge to platelet inhibition with clopidogrel in ST-segment myocardial infarction (STEMI) during percutaneous coronary intervention (PCI) to prevent stent thrombosis. However, ticagrelor and prasugrel reach similar levels of platelet inhibition at 30 minutes to that of clopidogrel at 6 hours, challenging the need for long-duration tirofiban. This 1-year, retrospective cohort study compared ischemic and bleeding outcomes of short-duration versus long-duration tirofiban regimens in patients with STEMI who received ticagrelor or prasugrel at the time of PCI. The primary...
Source: Journal of Cardiovascular Pharmacology - July 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Association between GNAQ Gene DNA Methylation and Vascular Recurrence in Patients with Acute Ischemic Stroke or Transient Ischemic Attack
Conclusions: Hypomethylation of CpG 32 –39 of GANQ gene was associated with a higher risk of ischemic events for clopidogrel-treated acute ischemic stroke or TIA patients. Further studies were warranted to explain the possible mechanism.Cerebrovasc Dis
Source: Cerebrovascular Diseases - June 28, 2022 Category: Neurology Source Type: research

EE165 Cost-Effectiveness Analysis Model of Aspirin and Aspirin Combination Therapy in Acute Ischemic Stroke Patient in West Sumatera
Aspirin usage as monotherapy in acute ischemic stroke has been well-documented as the therapeutic option for early stroke management and recurrent stroke prevention. Recent studies have shown the potential of aspirin combination (dual antiplatelet therapy with clopidogrel) in effectively decreasing the possibility of recurrent stroke. Despite the promising clinical effectiveness, a cost-effectiveness model was built to compare these two options.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: N Fitria, F Putrizeti, YO Sari Source Type: research

Effects of Different Doses of Clopidogrel plus Early Rehabilitation Therapy on Motor Function and Inflammatory Factors in Patients with Ischemic Stroke
Evid Based Complement Alternat Med. 2022 Jun 14;2022:9692382. doi: 10.1155/2022/9692382. eCollection 2022.ABSTRACTThis prospective randomized controlled study was intended to assess the effects of different doses of clopidogrel plus early rehabilitation therapy on motor function and inflammatory factors in patients with ischemic stroke. Between August 2018 and October 2020, 90 cases of ischemic stroke treated in the Second People's Hospital of Yibin were randomized at a ratio of 1 : 1 to receive either oral 50 mg/d clopidogrel plus early rehabilitation therapy (low-dose group) or oral 75 mg/d clopidogrel plus early rehabil...
Source: Evidence-based Complementary and Alternative Medicine - June 24, 2022 Category: Complementary Medicine Authors: Zhuolin Zhao Ying Ma Qin Liu Ling Jiang Huimin Shu Daofeng Chen Jiao Wu Source Type: research

No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke
CONCLUSIONS: No rebound increase in the risk of ischemic stroke and composite events was found during the 90 days after discontinuation of clopidogrel therapy in patients with TIA or minor stroke in the CHANCE trial.TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.PMID:35695332 | DOI:10.1080/01616412.2022.2075660
Source: Neurological Research - June 13, 2022 Category: Neurology Authors: Xinmiao Zhang Jing Jing Xingquan Zhao Liping Liu Anxin Wang Yuesong Pan David Wang S Claiborne Johnston Yilong Wang Yongjun Wang Xia Meng Source Type: research